Project Grant R01CA302883
Award Date 7/7/26
Completion Date 7/1/31
Dollars Obligated $563K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Washington University a Project Grant totaling $399,829 on May 14, 2026, under the Cancer Treatment Research program (CFDA 93.395) to enhance the efficacy of neoantigen cancer vaccines. The research, conducted at the institution's St. Louis, Missouri facility through April 30, 2028, focuses on addressing the low immunogenic response of current cancer vaccine formulations by targeting Type 1 Regulatory T cells (Tr1), which...
- Federal Grant Award Summary The National Cancer Institute awarded Washington University a $399,829 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2026 through June 30, 2028. This grant supports fundamental research to elucidate the mechanisms underlying ADAR1 (Adenosine Deaminase Acting on RNA 1)-regulated serine metabolism and to identify novel therapeutic opportunities targeting these metabolic vulnerabilities in triple-negative breast cancer...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a $155,500 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2028. The award funds research to identify and characterize mutation-induced alternative splicing (MAS) events in cancer using multi-omics data. The project leverages existing sequencing data from the Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $3,182,665 (Award Date: September 24, 2025; Completion Date: August 31, 2029) under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of natural killer (NK) cells in immune checkpoint therapy (ICT) of cancer. The research will elucidate the mechanisms by which NK cells constrain the effectiveness of ICT, evaluate the contribution of the NKG2D...
- Federal Project Grant Award Summary Funding Agency & Program: The National Cancer Institute (NCI) awarded $399,829 under the Cancer Treatment Research program (CFDA 93.395) on May 13, 2026, to Washington University's Office of Sponsored Research Services. Research Deliverables: This project grant funds mechanistic research and development of a novel dendritic cell (DC)-based cancer immunotherapy designated AB7H3-TLR4 CAR-DCs (Chimeric Antigen Receptor Dendritic Cells). The research...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Washington University a $542,644 Project Grant effective April 1, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and preclinical evaluation of radiation-guided antibody-drug conjugates (ADCs) designed to improve treatment outcomes for non-small cell lung cancer (NSCLC). The research leverages a breakthrough discovery identifying...
- Federal Grant Award Summary The National Cancer Institute awarded a $399,829 Project Grant to The Washington University (Office of Sponsored Research Services) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026, through March 31, 2028. This project focuses on the rational design of next-generation engineered T cells to enhance cancer immunotherapy by addressing a critical limitation in current chimeric antigen receptor (CAR) T cell treatments—limited...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded a $532,127 Project Grant to The Washington University Office of Sponsored Research Services effective July 1, 2026, with completion targeted for June 30, 2031. The grant funds research evaluating the therapeutic index of Tax-Interacting Protein 1 (TIP1)-targeted beta and alpha radioimmunotherapy for non-small cell lung cancer (NSCLC) treatment. The research team...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $615,399 Project Grant to the University of California, Davis under the Cancer Treatment Research program (CFDA 93.395) for the period August 1, 2025, through July 31, 2030. The award supports the development of a transformable nanoparticle (TNP) platform designed to deliver therapeutic peptides and proteins directly to tumor microenvironments on-demand. The TNP technology transforms from nanoparticles to nanofibrils...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $645,185 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on May 15, 2026, with completion anticipated by April 30, 2031. This award supports research to develop and evaluate a novel combination immunotherapy approach for glioblastoma, a highly aggressive brain tumor with poor patient survival outcomes. The project, titled "Expand and Pull: Long-Acting IL-7 and Oncolytic...